# CURRICULUM VITAE

**TODD S. WILLS, M.D., FACP**

University of South Florida, Morsani College of Medicine, Tampa, Florida

# MAILING ADDRESS:

University of South Florida Morsani College of Medicine Physician Assistant Program

12901 Bruce B. Downs Blvd., MDC 5 Tampa, FL 33612

Phone (813)974-3504

Fax (813) 905-9860

e-mail: [twills@usf.edu](mailto:twills@usf.edu)

# EDUCATION:

University of South Florida College of Medicine, Tampa, Florida, 1998, M.D Rollins College, Winter Park, Florida, 1994, B.A., summa cum laude, valedictorian.

# POSTGRADUATE TRAINING:

Fellowship, Infectious Diseases and Tropical Medicine, University of South Florida College of Medicine, Tampa, Florida, July 2001- June 2003.

Residency, Internal Medicine, University of North Carolina Hospitals, Chapel Hill, North Carolina, 1998-2001.

*Board Certification*:

Internal Medicine - American Board of Internal Medicine, 2001, recertified 2011 Infectious Diseases - American Board of Internal Medicine, 2003, recertified 2013 *License*: Florida License: ME84242, Active, originally issued February 2002

# HONORS AND AWARDS:

Outstanding Didactic Year Instructor - USF Morsani College of Medicine PA Program, 2019, 2020

America's Best Doctors 2009-2020 (inclusive)

USF Morsani College of Medicine - Department of lnternal Medicine, Excellence in Education Award. 2018.

USF Health Platinum Incentive Award- 2007, 2011

Outstanding Junior Faculty Member USF Division of lnfectious Disease and Internal Medicine - February 2007.

Florida Liver Association- Inspiration of Hope Award, May 2005.

Tampa General Healthcare Basic Science Scholar Award, University of South Florida College of Medicine, Tampa, Florida, 1998.

Clinical Pharmacology Award for Excellence, University of South Florida College of Medicine, Tampa, Florida, 1998.

Medical Microbiology and Immunology Award for Excellence, University of South Florida College of Medicine, Tampa, Florida, 1998.

Alpha Omega Alpha, junior initiate, University of South Florida College of Medicine, Tampa, Florida, 1997.

Barry M. Goldwater National Scholarship for Excellence in Science and Engineering, Rollins College, Winter Park, Florida, 1993.

# APPOINTMENTS:

### Academic:

Professor, University of South Florida Morsani College of Medicine, Department of lnternal Medicine, Division of lnfectious Diseases, August 2020-present.

Associate Professor, University of South Florida Morsani College of Medicine, Department of lnternal Medicine, Division of lnfectious Diseases, August 2009 – July 2020

Assistant Professor, University of South Florida College of Medicine, Department of Internal Medicine, Division of lnfectious Diseases, July 2003- July 2009.

### Administrative:

Associate Dean and Director, USF Health Continuing Professional Education, June 2019 -present

Assistant Dean and Program Director - USF Morsani College of Medicine Physician Assistant Program, August 2015 - present

Medical Director, Rohr Home- Skilled Nursing Facility, Polk County (Florida) July 2014-present

Vice-Chair for Research, Education and Operations - Department of lnternal Medicine, University of South Florida Morsani College of Medicine, December 2012-15.

Medical Director. Polk County (Florida) Health Plan; November 2011-Present

Program Director, Infectious Diseases Fellowship, University of South Florida Morsani College of Medicine, Department of Internal Medicine, April 2009 September 2015.

Assistant Program Director, Infectious Diseases Fellowship, University of South Florida College of Medicine, Department of lnternal Medicine, July 2003 -March 2009.

Associate Director, Florida STD/HIV Prevention Training Center: CDC National Network of STD/HIV Prevention Training Centers, July 2003 - 2010.

Assistant Clinical Director, Signature Interdisciplinary Program in Allergy, Immunology and Infectious Disease, July 2005 - 2009.

### Hospital appointments:

Tampa General Hospital Active Medical Staff, Infectious Diseases Section, 2003- present

James A. Haley VA Hospital, Tampa, FL Active Medical Staff, 2009-present

Medical Director, Complex Medicine Unit - Tampa General Hospital; March 2010 - 2015

# TEACHING:

**MORSANI COLLEGE OF MEDICINE COURSES:**

## PA Program:

*PAS 6011 Clinical Medicine I,* teaching faculty, 2017-present

*PAS 6013 Evidence Based Medicine,* teaching faculty, 2019-present

*PAS 6033B Clinical Medicine II,* teaching faculty 2017-present

*PAS 6023 Clinical Pharmacology I,* teaching faculty, 2019-present; co-course director 2021

PAS 6026 Clinical Pharmacology II, teaching faculty 2019 - present

*PAS 6028 Pathophysiologic Basis of Disease I, teaching faculty 2021*

*PAS 6032 Clinical Laboratory and Diagnostics II,* teaching faculty, 2017-present

*PAS 6033 Clinical Medicine III,* teaching faculty 2018-present

*PAS 6036 Physical Diagnosis I,* teaching faculty, 2017-present

*PAS 6037 Physical Diagnosis II,* teaching faculty, 2017-present

*PAS 6039 Advanced Clinical Pharmacotherapeutics,* course director, 2018-present

**MD Program**

*MEL 7310 Infectious Diseases and Tropical Medicine,* Tampa General Hospital, 2003- 2015:

4th year medical student elective.

*MEL 8357 Injections in Transplant Medicine.* Tampa General Hospital, 2003-2015: 4th year medical student elective.

*MEL 8363 Infections in the Intensive Care Unit.* Tampa General Hospital, 2003-2015: 4th year medical student elective.

*MEL 8365 Outpatient Care of the HIV Infected Patient,* USF Medical Clinic/ Hillsborough County Health Department, 2004-2015: 4th year medical student elective.

*EMS 6941 Longitudinal Clinical Experience 2*004-2015: 1st and 2nd year medical student course - hands-on patient care experience.

CC *8190 Critical Care Clerkship I & II*  2006-2015: 4th year medical student requirement. Small Group Leader - Sepsis.

*PHC 6510* - *Emerging Infectious Diseases (COPH)* - 2006-2007. Global Epidemiology of HIV/AIDS.

*Scholarly Concentration in International Health.* Elective student scholarly concentration. Student research mentor, 2007 - 2015.

*EMS 6826 -Doctoring 2 SELECT* Small Group Preceptor 2013-2015

## Graduate Medical Education:

*Infectious Diseases Basic Science Conference,* 2003-2015 (Course Director). Weekly lecture course for Infectious Diseases Fellows, Internal Medicine residents, medical students.

*Infectious Diseases Clinical Case Conference,* 2003 - 2015 (Course Director). Weekly case-based for Infectious Diseases Fellows, Internal Medicine residents, medical students.

*Infectious Diseases Research Conference,* 2007- 2015 (Course Director). Monthly conference focusing on research methodology and ongoing research by Infectious Diseases fellows.

*Infectious Diseases Journal Club,* 2003-2015 (Course Director). Journal club for Infectious Diseases Fellows.

*Introduction to Infectious Diseases, USF Infectious Disease Fellowship Training Annual Series,* 2003-2015. Introductory lecture series for Infectious Diseases Fellows.

*K30 Scholars Program.* 2006- 2013. Lecturer. Ethical Considerations in Minority Recruitment to Clinical Trials and International Medical Research.

*Basic Medicine Lecture Series,* Tampa General Hospital, 2003-2015. Introductory lecture series for Internal Medicine residents.

*Internal Medicine Resident Rotation, Medical Service Noon Conference Series,* Tampa General Hospital, 2003-2015. Basic science lecture series for Internal Medicine residents, medical students.

# INFECTIOUS DISEASES FELLOWS TRAINED AS PROGRAM DIRECTOR:

|  |  |  |
| --- | --- | --- |
| 2003 | Lucinda Elko, M.D. Christopher Cooper, M.D. | Michael Tan, M.D. |
| 2004 | Shereen Saba, M.D.  Philbert Ford, M.D. | Aaron Cooks, M.D.  Beata Herman (Casanas), D.O. |
| 2005 | Patricia Leon, M.D.  Charlie Phillips, M.D. | Ana Velez, M.D.  Igor Melnychuk, M.D. |
| 2006 | Juan Diaz, DO  Anibal Maldonado, MD | Abbigail Chandler, MD  Javier Marinez, MD |
| 2007 | Daniela Chiriboga, MD Yagneshvari Patel, DO | Chakrapol Sriaroon, MD |
| 2008 | Michelle Mizrachi, M.D. | Tri Pham, M.D.  Theingi Oo, M.D. |
| 2009 | Sally Alrabba, MD Aliyah Baluch, MD Fariba Donovan, MD | Dhanashree Kelkar, MD Tran Phung, MD Marela Velez, MD |
| 2010 | Moise Carrington, MD Elvis Castillo, MD | Ulyee Choe, DO Rachel Franck, MD |
| 2011 | Joseph Katta, MD  Elias Maroun, MD Tienchai Narach, MD | Georgina Nasr, MD  Luis Rosas, MD Kevin Smith, MD |
| 2012 | Christine Ayarza. MD Patrick Kenney, DO | Pamela Damisse, MD Phuong Nguyen, MD |
| 2013 | Joseph Halliday, DO Mitsuya Katayama, MD Rey Rivera, MD | Lily Jones, DO Nancy Rihana, MD  Vivian Vega, MD |
| 2014 | Illeana Acevedo, MD Jane Mai,MD  Suganya Manivannan, MD | Lysenia Mojica, MD  Jeniffer Torres-Velazco, MD |
| 2015 | Minh Ho,DO  Kelly Kynaston, DO Joseph Paruolo MD | Flor Sanchez Vargas, MD  Kaley Tash, MD |

**INVITED LECTURES:**

*International:*

"Clinical Complications of HIV and Tuberculosis Co-Infection" 6th National HIV Medicine Update. Center for Health and AIDS Research Training India (CHART-India), Ahmedabad, India. January 2007.

"HIV and Viral Hepatitis Co-Infections - Clinical Considerations" 5th National HIV Medicine Update. Center for Health and AIDS Research Training India (CHART-India), Mumbai, India. January 2006.

"Management of HIV/Hepatitis B Co-Infection" 4th National HIV Medicine Update. Center for Health and AIDS Research Training India (CHART-India), Mysore, India. January 2005.

"Post Exposure Prophylaxis versus Blood-Borne Pathogens" 3rd National HIV Medicine Update. Center for Health and AIDS Research Training India (CHART-India), Vadodara, India. January 2004.

"Case Presentations in HIV Medicine" 1st Annual Summit in HIV Medicine. Vasai Regional AIDS Control Society, Vasai, India. January 2004.

"HIV and Hepatitis Co-Infection: Clinical Challenges" 2nd National HIV Medicine Update. Centre for Health and AIDS Research Training India (CHART-India), Pune, India. January 2003.

"Opportunistic Infections Complicating HIV" 2nd Annual Certificate Course in HIV Medicine. CHART-India, Ruby Hall Clinic Department of HIV Medicine, Pune, India. January 2003.

*National:*

Evolution of HCV Therapy in the Era of Direct Acting Antivirals - Annual Grantee Meeting. HRSA Special Projects of National Significance - Hepatitis C Treatment Expansion Initiative. Washington DC, March 2013

Implementing HCV Treatment Programs in Comprehensive HIV Clinics. Workshop - Ryan White 2012 Grantee Meeting. Washington DC. November 29, 2012

Initial Lessons of the HRSA/SPNS Hepatitis C Treatment Expansion

Initiative. Presented to the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis,

STD Prevention and Treatment (CHAC) - Washington DC. December 11, 2012

"2011 Update in HIV/HCV Management in the Era of Direct Acting HCV Antivirals" 2nd Annual Grantee Meeting. HRSA Special Projects of National Significance - Hepatitis C Treatment Expansion Initiative. Washington DC, November 2011.

"Future Directions in HIV/HCV Therapy" 1st Annual Grantee Meeting. HRSA Special Projects of National Significance - Hepatitis C Treatment Expansion Initiative.

Washington DC, January 2011.

"The Medical Consequence of AIDS Drug Assistance Program Waiting Lists" Congressional Briefing ADAP Advocacy Association. Russell Senate Office Building, Kennedy Caucus Room, Washington, DC September 2010.

"Caring for the Treatment-Experience Patient: Essential Information for Nurses" 20th Annual Conference Association of Nurses in AIDS Care. Orlando, November 2007.

"India at the Crossroads: HIV/AIDS 2005" 18th Annual Conference Association of Nurses in AIDS Care. Orlando, Florida. November 2005.

*Regional:*

HIV/HCV Coinfection in the Era of Direct Acting HCV Antivirals - HIV Lecture Series, St. Jude Children's Research Hospital, June 2015.

"HIV and Hepatitis C Co-infection: Current Standards and New Paradigms" 21st Annual HIV Conference. Florida Caribbean AIDS Education and Training Center, Orlando,

Florida. October 2012

"Interpretation of Antiretroviral Resistance Testing" 19th Annual HIV Conference - Florida Caribbean AIDS Education and Training Center, Orlando, Florida. May 2010.

"Antimicrobial Resistance and New Antibiotics" 20010 Family Medicine Review, St. Petersburg, Florida. March 2010.

"Access and Treatment Disparities in HIV/AIDS in the US" Florida ACP Chapter Scientific Meeting, St. Petersburg, Florida. September 2009.

"Antiretroviral Therapy in Treatment Experienced Patients" 18th Annual HIV Conference

- Florida Caribbean AIDS Education and Training Center, Orlando, Florida. May 2009.

"Treatment Disparities in HIV/AIDS" 2009 Family Medicine Review, St. Petersburg Florida. March 2009.

"Current Issues with Sexually Transmitted Infection Management for the HIV Provider" Keeping with the Pace XVII: An HIV Update, Gainesville, Florida. May 2008.

"Analyzing HIV Clinical Trial Data" 17th Annual HIV Conference - Florida Caribbean AIDS Education and Training Center, Orlando, Florida. March 2008.

"Antiretroviral Therapy and Management of Multiple Co-Morbidities in HIV Patients." 15th Annual HIV Conference - Florida/Caribbean AIDS Education and Training Center, Orlando, Florida. March 2006.

"Antiretroviral Therapy and Management of Multiple Co-Morbidities in HIV Patients." 15th Annual HIV Conference - Florida/Caribbean AIDS Education and Training Center, Orlando, Florida. March 2006.

"Breakthroughs and Challenges - the next generation of HIV/AIDS" Keynote Address - World AIDS Day Breakfast, Manatee County, Florida. November 2007.

"Recognition of HIV Drug-Drug Interactions" 16th Annual HIV Conference - Florida/Caribbean AIDS Education and Training Center, Orlando, Florida. March 2007.

"Antiretroviral Therapy: Guidelines for initial treatment of HIV in Adults"

14th Annual HIV Conference - Florida/Caribbean AIDS Education and Training Center, Orlando, Florida. April 2005.

"Hepatitis C ... Where are We Going and Where Have We Been" Hemophilia of Indiana Annual Meeting, Indianapolis. August 2004.

"Hemophilia and Hepatitis C" National Hemophilia Conference, Tampa, Florida. May 2004.

Clinical Manifestations of Adult and Congenital Syphilis" Syphilis Symposium, Miami Dade County Health Department, Florida STD Prevention and Training Center. Miami, Florida. November 2002.

**SCHOLARLY ACTIVITY:**

### Extramural grants:

Hyer, K (PI) Wills TS (co-investigator) et al.: HRSA USF Geriatric Workforce Enhancement Project. Total Grant $2.4 million - 8% USF effort

Sinnott, JT, Wills TS (Co-Investigator) HRSA- Special Programs of National Significance Hepatitis C Treatment Expansion Imitative Evaluation and Technical Assistance Center (ETAC) U90HA19469-0l-00 Total Grant $1.7 million (9/2010- 8/2014) 25% USF effort (refereed)

Emmanuel, P. (PI) Wills, TS (Co-Investigator) et al. - National Institutes of Health - Fogarty International Center: Program in Adolescent HIV/AIDS Research Training (PAHRT) 1D43TW006793-01A2 Annual $273,000 Duration: 09/11/2007 - 06/30/2012: 5% USF Effort (refereed)

Knox M (PI), Wills, TS (Co-Investigator), et al. Florida/Caribbean AIDS Education and Training Center. HRSA, 2003-2015. $201,174 average annually: 10-40% USF Effort (refereed)

Toney JF Wills, TS (Co-Investigator), et al. Southeast Region STD/HIV Prevention Training Center. Centers for Disease Control. 2003 - 2010; $396,000 annually. 30% USF Effort (refereed)

Gompf S (PI), Wills, TS (Co-Investigator), et al. Region IV South Ryan White Care Act Title III Program for Outpatient Early Intervention Services with Respect to HIV Disease, NIH/Hemophilia of Georgia, 2004-2005, 504 patients enrolled, $382,500: 22% USF effort (refereed)

***Clinical research protocols:***

## Protocols (Principal Investigator):

A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS 9137 (GS 9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV 1 Infected Subjects.

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment- Naive Adults [Protocol: GS-US-292-0104].

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults. [Protocol: GS-US-292-0111]

A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAP-Containing Combination Single Table Regimen (STR) in Virologically Suppressed, HIV-1 Subjects [Protocol: GS-US-292-0109]

A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment [Protocol: GS-US-292-0112]

A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults [Protocol No. GS-US-292-0117]

A Phase 3 Open-label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults [Protocol No. GS0US-292-0119]

A Phase 3, Randomized, Double-Blind, to evaluate Switching from a Regimen Consisting of EFV/FTC/TDF FDC to FTC/RPV*IT* AF FDC in patient with virologically controlled HIV-I infection [Protocol No. GS-US-366-1160]

A Phase 3, Randomized, Double-Blind, to evaluate Switching from a Regimen Consisting of FTC/RPV/TDF FDC to FTC/RPV*IT* AF FDC in patient with virologically controlled HIV-I infection [Protocol No. GS-US-366-1216]

## Protocols (Co-Investigator)

A randomized, controlled, partially blinded Phase Ilb dose-finding trial ofTMC125, in HN-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations. [TMC125-C223)

A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HN-1 Infected, Treatment-Naive Subjects, with a 12-Week Extension Treatment Period. [ACH443-015)

A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. [SMART CPCRA 065)

A randomized, controlled, open-label trial to compare the efficacy, safety, and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1 infected subjects. This trial will be referred to as ARTEMIS. [TMC 114-211)

A Phase Ilb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral Naïve HlV-1 Infected Subjects. [TMC278-204]

An Open-Label Trial with TMC125 in HN-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and were Treated for at least 48 Weeks. [TMC125-C229]

A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects. [EPZ104057] -HEAT

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination. [COL100758)

A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HN-1) gag Vaccine in HIV-1 Infected Individuals. [Merck V520-014]

A Randomized, Controlled, Open-Trial to Compare the Efficacy, Safety and Tolerability of TMC 114/RTV versus LPV/RTV in Treatment-Experienced HlV-1 Infected Subjects. [TMC 114-C214]

Double-blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects.

A Double-Blind, Randomized, Placebo-Controlled Study of Two Doses of Capravirine (AG1549) in Combination with Nelfinavir and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen

The Safety and Antiviral Efficacy of Stavudine Extended-Release Formulation as compared to Stavudine Immediate Release Formulation, Each as part of Potent Antiretroviral Combination Therapy.

A Phase 3, Open-Label, Multi-center Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients.

A Phase 3, Randomized, Multi-center, Parallel, Open-label study to compare the Efficacy, Safety, and Tolerability of GW433908 1395 mg bid and Nelfinavir 1250 mg bid over 48 weeks in Antiretroviral Therapy Naive HIV-I Infected Adults.

Resistance Testing of HIV-Infected Patients Entering Therapy. A Randomized, Open­ Label Study Evaluating the Tolerability of a Lopinavir/Ritonovir-based versus Indinavir­ based Post-Exposure Prophylaxis (PEP) Expanded Regimen for High-risk Occupational Exposures.

A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-I Infected Individuals.

PEG-Interferon alfa-2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV­ Infected Persons Not Previously Treated with Interferon.

A review of adherence to U.S. Public Health Service/ Infectious Diseases Society of America guidelines for the care of HIV/ Hepatitis C co-infected patients.

A Multicenter Randomized, Double-Blind, Controlled Study ofNGX-4010 for the Treatment of Painful HIV-Associated Neuropathy. [NGX-C119]

A Randomized, Open-Label Trial to Compare the Efficacy, Safety and Tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in Early Treatment­ Experienced HIV-I Infected Subjects. [TMCI 14-C229]

A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability, and safety ofTMC125 as part of an ART including TMCI 14/RTV and an investigator-selected OBR in HIV-I infected subjects with limited to no treatment options. [TMC125-C206]

A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-I Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy. [GS-US-183-0105]

Evaluating the Diagnostic Performance of an HIV Assay to detect antibodies in Urine Specimens

A Multicenter, Randomized, Blinded, Placebo-Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HN-1-Infected Subjects Co-Infected With Hepatitis C and/or Hepatitis B Virus

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS- 9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir­ Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy versus Optimized Background Therapy along for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. [Pfizer A4001027]

**PUBLISHED BIBLIOGRAPHY:**

*Original Publications in Peer-Reviewed Journals:*

Larkin JA, Lit L, Sinnott JT, **Wills TS,** and Szentivanyi A. Infection of a Knee Prosthesis with *Tsukamurella* Species. *Southern Medical Journal* 92: 831, 1999.

**Wills TS,** Nadler JP, Somboonwit C. Anemia Prevalence and Associated Risk Factors in a Single-Center Ambulatory HIV Clinical Cohort. *AIDS Reader* 14(6): 305-15. 2004.

**Wills TS,** Degryse A, Lavina J, Sinnott JT. *Blastoschizomyces Capitatus* Pneumonia in an Immunocompetent Male. *Southern Med* J97(7): 702-4, 2004.

Irvine L, **Wills TS.** *Streptobacillus moniliformis:* A mouse trying to become a rat. *Clin Micro Newsletter* 28 (15): 118-20, 2006.

**Wills TS,** Lopez J, Billington A. Empyema caused by *Ralstonia Picketii* in a Hemodialysis Patient. *Clin Micro Newsletter* 29 (7): 55-6, 2007.

**Wills, TS,** Vega, V. Elvitegravir: A Once-daily inhibitor ofHIV-1 Integrase. *Expert Opin. Invest. Drugs.* 21(3) 395-401, 2012.

Alrabaa S, Noel P, **Wills T.** Clostridium difficile Infection: What You Need to Know. *Consultant360* June 24, 2013 ([www.consultant360.com/artic1e/clostridium­](http://www.consultant360.com/artic1e/clostridium) difficile0infection-what you-need-to-know)

Rolfe NE, Haddad TJ, **Wills TS.** Management of *Scedosporium apiospermum* in a pre­ and post-lung transplant patient with cystic fibrosis. *Medical Mycology Case Reports* 3(2013) 37-39.

Montero, *IA,* Alrabaa SF, **Wills, TS** Mycobacterium abscessus ventriculoperitonal shunt infection and review of the literature. *Infection*. Published online 07 July 2015.

Hyer,K, Jester D, Badana, A, D' Aoust, R, Robinson B, Guerra L, Michael M, Molinari V, Schwartz A, Schocken D, **Wills T,** Wilson C, Andel R. Medical Faculty Beliefs: Self­ Rated Importance and Confidence in Teaching Geriatrics Primary Care. *Journal of the American Geriatrics Society*. Published online 14 January 2019.

*Book Chapters:*

**Wills TS,** "Gastrointestinal Infections in Cancer Patients" Infections in Cancer Patients, Ed. John N Greene. New York: Marcel Dekker, 2004. 313-30.

Menezes L, **Wills TS,** D'Souza K. "HIV/AIDS Among Asian and Pacific Islander Americans" Psychiatric Aspects of HIV/AIDS. Ed. Francisco Fernandez. Philadelphia: Lippincott Williams, 2005. 232-40.

**Wills TS,** Symes S Chapter l 8 "Cytomegalovirus Infections" HIV/AIDS Primary Care Guide Ed. Beal J, Orick JJ Norwalk CT: Crown House. 2006.

**Wills, TS,** Sinnott, JT, Alrabaa S. "Viral Hemorrhagic Fevers" APIC Text of Infection Control and Epidemiology. Association for Professionals in Infection Control and Epidemiology. Philadelphia. 2009. 88-1 88-10.

Shapshak, P, Somboonwit C, Foley BT, Alrabaa SF, **Wills T** and Sinnott JT. "Zika Virus" Global Virology I. Ed. Shapshak P, Sinnott JT, Somboonwit C, and Kuhn J. New York: Springer-Verlag. 2015. 477-500.

Elkomy FF, Levine A, Singer E, Somboonwit C, **Wills T,** Tash K, Sinnott JT, Alrabaa S, Addisu A, Rodriguez H, Chiappelli F, Shapshak P. "Neuronal Apoptotic Pathways in HIV-Associated Dementia, Alzheimer's Disease, Parkinson's Disease and Huntington's Disease. Global Virology II - HIV and NeuroAIDS. Ed. Shapshak P, et al. New York: Springer, 2017. 533-578.

*Invited Publications:*

**Wills TS.** Hepatitis C: The Epidemic comes out of Hiding. *HemAware* 9(6): 36-9, 2004.

**Wills TS.** Book Review: PDxMD Infectious Diseases Volumes 1 and 2. *Infections in Medicine* 21(10): 505-513, 2004.

Toney JF,**Wills TS.** Dermatologic Manifestations of Syphilis. *J Florida MA* 89(1)16-7, 2005.

Akhter, K, **Wills T,** Goodrich JM. Cytomegalovirus. EMedicine.com url: <http://www.emedicine.com/MED/topic504.htm>Updated May 5, 2018 (original 2009)

*Abstracts:*

Nadler JP, **Wills TS,** Somboonwit C, et. al. "Anemia Prevalence among HIV Patients: Anti-retroviral Therapy and Other Risk Factors" 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris 2003.

Tash K, **Wills T,** Sinnott J. *Rahnella aquatilis*: A New Niche? International Conference of Infectious Diseases. Lisbon, 2006.

Pujari S, **Wills T,** Naik E, Menezes L, et al. Correlates of Anemia for HIV patients in the HAART era: a single center ambulatory clinical cohort in Pune, India. XVI International AIDS Conference, Toronto 2006.

Naik E, D' Souza BS, Menezes L, **Wills T,** et. al. A Collaboratively designed HIV Mini­ residency by US and Indian Faculty. Association for Medical Education in Europe Conference, Genoa 2006.

Menezes L, D' Souza K, **Wills, T,** et al. Capacity-building: Indian Physicians Benefit from Blended Curriculum. Association for Medical Education in Europe Conference, Genoa 2006.

D'Souza KR, Menezes L, **Wills TS,** D'Souza KM. Women infected with HIV and Human Papillomavirus (HPV): an emerging health problem in resource-constrained settings. American Public Health Association (APHA) 134th Annual Meeting and Exposition, Boston 2006.

Nguyen, P. Alrabaa S, Joshi R, Kenney P, **Wills TS,** Montero J, Fluconazole resistance in cryptococcus neoformans: an emerging threat to the immune-compromised. IDWeek, San Diego 2012.

**Wills, TS.** Lindsey D. A Model for HCV Care Delive1y in a US Non-Governmental Medically Indigent Care Setting IDWeek, San Diego 2012.

**Wills, TS,** Friedrich M, Beal J, Somboonwit C, et al. Implementing Hepatitis C Treatment Programs in Comprehensive HIV Clinics: The Health Resources and Services Administration (HRSA) Special Projects of National Significance (SPNS) Hepatitis C Treatment Expansion Initiative. IDWeek. Philadelphia 2014.

**Wills, TS,** Friedrich M, Beal J, Somboonwit C, et al. Implementing Hepatitis C Treatment Programs in Comprehensive HIV Clinics: The Health Resources and Services Administration (HRSA) Special Projects of National Significance (SPNS) Hepatitis C Treatment Expansion Initiative. 201. Abstract 138 5 National Summit on HCV and HIV Diagnosis, Prevention and Access to Care. Arlington, VA 2015.

Jester DJ, Badana ANS, Andel R, D'Aoust R, Robinson B, Guerra L, Michael M, Molinari V, Schwartz A, Schoken D, **Wills T,** Wilson C, Hyer K. Validation of a Geriatric Clinical Educator Survey: Primary Care of Adults 60 Years and Older. Abstract. Association for Gerontology in Higher Education. Atlanta, GA 2018.

# SERVICE:

***University Service:***

## Committees:

*College of Medicine:*

Chair, USF Morsani College of Medicine Family Medicine Department Chair Search Committee, 2021.

USF Morsani College of Medicine Special Committee on Appointment, Promotion and Tenure Guidelines, 2015 - 2017.

USF Morsani College of Medicine, Appointment, Promotion and Tenure Committee, October 2014-October 2015

Steering Committee Member, University of South Florida Physician Assistant Program, October 2014- Present

USF Physicians Group Board of Directors - September 2013 - 2015

University of South Florida Graduate Medical Education Committee. July 2003-2015.

Scientific Review Committee, USF Health Clinical and Translational Science Institute, August 2011- 2013.

USF College of Medicine Faculty Council- September 2006 - 2010

*Department:*

USF Morsani College of Medicine, Department of lnternal Medicine, Promotion and Tenure Committee, 2013 – present

USF Morsani College of Medicine, Physician Assistant Program, Curriculum Committee – Chair, 2016-present

USF Morsani College of Medicine, Physician Assistant Program, Admissions Committee – Chair, 2016-present

USF Morsani College of Medicine, Physician Assistant Program, Academic Performance and Professionalism Committee – Chair, 2016-present

*Hospital/Medical:*

Tampa General Hospital Bylaws Committee 2014 - present

Tampa General Hospital Professional Credentials Committee. January 2007 - present.

Tampa General Hospital Pharmacy and Therapeutics Committee, January 2011 - 2016.

Chair, Polk County Health Plan Pharmacy and Therapeutics Committee, January 2012 - 2015.

Chair, Polk County Health Plan Medical Management Committee, January 2012 - 2015. Tampa General Hospital Infection Control Committee, January 2011 - 2013.

Tampa General Hospital Cardiac and Lung Transplant Team. July 2003 - 2012.

### Organizing Roles in Scientific Meetings:

2nd Annual Symposium Signature Interdisciplinary Research Program in Allergy, Immunology, and Infectious Disease - "Immunity and Pathogens" Tampa, May 2008.

### Community Service and Education:

Judea-Christian Clinic Tampa, FL Volunteer Physician: Hepatitis C evaluation and treatment clinic, 2001 - present

### Professional Societies:

Fellow -American College of Physicians, 2017 - present Member, Infectious Diseases Society of America 2001 - present